T. Rowe Price Associates’s Rapport Therapeutics RAPP Stock Holding History

T. Rowe Price Associates’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.8M	Sell	787,446 -79,010	-9%	-$2.9M	﹤0.01%	1008
2026 Q1	$27.1M	Sell	866,456 -15,153	-2%	-$426K	﹤0.01%	962
2025 Q4	$26.7M	Sell	881,609 -220,782	-20%	-$6.11M	﹤0.01%	993
2025 Q3	$32.7M	Sell	1,102,391 -423,128	-28%	-$7.55M	﹤0.01%	923
2025 Q2	$17.3M	Buy	1,525,519 +452,311	+42%	+$4.8M	﹤0.01%	986
2025 Q1	$10.8M	Sell	1,073,208 -70,176	-6%	-$911K	﹤0.01%	1100
2024 Q4	$20.3M	Buy	1,143,384 +95,976	+9%	+$2.13M	﹤0.01%	995
2024 Q3	$21.5M	Sell	1,047,408 -313,197	-23%	-$6.73M	﹤0.01%	979
2024 Q2	$31.6M	Buy	+1,360,605	New	+$31.5M	﹤0.01%	845

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

T. Rowe Price Associates's RAPP Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Rapport Therapeutics (RAPP) stake by 9.1% in Q2 2026, selling an estimated $2.9M and leaving 787,446 shares worth $32.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

T. Rowe Price Associates first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

T. Rowe Price Associates held 787,446 shares of Rapport Therapeutics worth $32.8M as of Q2 2026.
T. Rowe Price Associates sold 79,010 Rapport Therapeutics shares in Q2 2026, an estimated $2.9M.
Rapport Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1008 holding.
T. Rowe Price Associates first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.